HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Who You Gonna Call For US Oral Contraceptive Switch? Former FDA Official Heads Perrigo Americas

Executive Summary

Jim Dillard, chief scientific officer for Perrigo since 2019, moves to head the North American business with research and development experience as well as a regulatory background from his work at the FDA.

You may also be interested in...



HBW Executive Decisions: Perrigo Science Chief, Clasada Supply Manager, FTC Appointment, More

Democrat majority at FTC with Bedoya confirmation; Ives leads Perrigos science office; ACI appoints legal affairs director; Biomega promotes Norway factory manager; first leader for BBB National Programs’ outreach center; Embion adds commercial VP; and Clasado adds supply chain, corporate marketing heads.

Perrigo Debuts On US National Brand Stage With OTC Switch Approval For Nasonex 24HR Allergy

Nasonex 24HR Allergy also will be first OTC mometasone furoate product available in US. It will compete in OTC intranasal corticosteroids category already led by other brands switched from Rx to nonprescription over past eight years.

Perrigo Feels Chill From Q3 Results Due To ‘Unfulfilled’ Demand On Supply Chain Disruptions

“Unfulfilled orders' from retailers and other product distributors due to supply chain disruptions slowed revenues, net income and earnings per share during the quarter and prompted lower full-year guidance while also leaving analysts with doubts.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

RS151820

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel